Published in:
01-02-2015 | Original Article
Predictors of re-fracture amongst patients managed within a secondary fracture prevention program: a 7-year prospective study
Authors:
K. Ganda, A. Schaffer, M. J. Seibel
Published in:
Osteoporosis International
|
Issue 2/2015
Login to get access
Abstract
Summary
This 7-year prospective observational study determined the predictors of re-fracture amongst 234 patients managed within a Secondary Fracture Prevention programme. Poor compliance, multiple co-morbidities, corticosteroid therapy, low hip bone mineral density (BMD) or low body weight were all significantly associated with re-fracture in patients commenced on long-term anti-resorptive therapy.
Introduction
Risk factors for osteoporotic fracture amongst treatment-naïve patients are well established. In contrast, predictors of re-fracture in patients optimally managed within a Secondary Fracture Prevention (SFP) programme are ill-defined.
Methods
This prospective observational study included 234 subjects with incident osteoporotic fractures managed long-term by the Concord SFP programme. Using Cox proportional hazards models, predictors of re-fracture were analysed separately for patients commenced on specific pharmacotherapy (group 1, N = 171) and subjects receiving calcium and/or vitamin D supplements only (group 2, N = 63). Relevant anthropometric, clinical and technical data were documented at each visit. Compliance and persistence were analysed as time-varying covariates.
Results
During a mean follow-up of 5.2 (range 3.5–7.3) years, 20.9 % of all subjects re-fractured (26.3 % in group 1, 6.3 % in group 2). Multivariate predictors of re-fracture in group 1 were significant co-morbidity (HR 2.04 if >3, 95 % CI 1.10–3.79, p = 0.024), corticosteroid use (HR 1.75, 95 % CI 1.12–2.73, p = 0.013) and total hip BMD (HR 1.36 per 0.1 g/cm2 decrease, 95 % CI 1.08–1.70, p = 0.008). In contrast, gender, prevalent fractures and lumbar spine BMD were not associated with re-fracture. Amongst patients with complete compliance data, a medication possession ratio of ≤ 50 % (HR 3.36, 95 % CI 1.32–8.53, p = 0.011) and low body weight (HR 1.04 per 1-kg decrease, 95 % CI 1.003–1.08, p = 0.032) were significantly associated with re-fracture.
Conclusions
Amongst patients managed within a dedicated SFP programme, poor compliance, multiple co-morbidities, corticosteroid therapy, low hip BMD or low body weight are all associated with increased risk of re-fracture. This subgroup of patients therefore require intensive management including strategies to improve compliance.